On June 5, Zai Lab declined 5.05% in regular trading, trading at HK$12.56/share, with trading volume of HK$134 million. The stock has now fallen approximately 20% over the past month, reflecting sustained selling pressure.

On the news front, the company previously reported Q1 total revenue of US$99.6 million, representing a 6% year-over-year decline. Additionally, the departure of President and COO Josh Smiley has raised market concerns over management stability, following the earlier exit of the Chief Commercial Officer. The biotech sector broadly weakened on the same day, with Akeso down 4.02%, BeiGene down 2.92%, and 3SBio down 2.57%, amplifying negative sentiment on individual names. Morgan Stanley previously maintained an Overweight rating on the stock with a target price of HK$19, implying significant upside from current levels.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)